Expression of PD-L1 is the key determinant for frontline immunotherapy selection in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) because patients can benefit greatly from PD-1/PD-L1
Search Results
NCCN Guidelines Updates: New Immunotherapy Strategies for Improving Outcomes in Non–Small Cell Lung Cancer
Matthew A. Gubens and Marianne Davies
Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Angel Qin, Songzhu Zhao, Abdul Miah, Lai Wei, Sandipkumar Patel, Andrew Johns, Madison Grogan, Erin M. Bertino, Kai He, Peter G. Shields, Gregory P. Kalemkerian, Shirish M. Gadgeel, Nithya Ramnath, Bryan J. Schneider, Khaled A. Hassan, Nicholas Szerlip, Zoey Chopra, Sara Journey, Jessica Waninger, Daniel Spakowicz, David P. Carbone, Carolyn J. Presley, Gregory A. Otterson, Michael D. Green, and Dwight H. Owen
Background More than one-third of patients with metastatic non–small cell lung cancer (mNSCLC) will develop bone metastases during the course of their illness. 1 Development of bone metastases often leads to significant morbidity, with
Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer
Dong Ding, Huabin Hu, Shuosha Li, Youwen Zhu, Yin Shi, Mengting Liao, Jin Liu, Xu Tian, Aiting Liu, and Jin Huang
Background Lung cancer remains the leading cause of cancer incidence and mortality, with 2.1 million new lung cancer cases and 1.8 million deaths in the United States. 1 , 2 Approximately two-thirds of patients with small cell lung cancer
Lung Cancer Screening
Peter B. Bach
The author has no financial interest, arrangement, or affiliation with the manufacturers of any products discussed in the article or their competitors. References 1. Aisner J . CT screening for lung cancer: are we ready for
Management of Patients With Resectable and Metastatic Non–Small Cell Lung Cancer
Presented by: Jane Yanagawa and Gregory J. Riely
Non–small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 84% of all lung cancer diagnoses. It is estimated that nearly 200,000 adults will be diagnosed with NSCLC in the United States in 2022. In addition to
Harmonized Outcome Measures for Use in Non–Small Cell Lung Cancer Patient Registries and Clinical Practice
Martin J. Edelman, Daniel P. Raymond, Dwight H. Owen, Michelle B. Leavy, Kari Chansky, Sriram Yennu, Felix G. Fernandez, Carolyn J. Presley, Tithi Biswas, Gwendolyn P. Quinn, Matthew B. Schabath, Seth Sheffler-Collins, Laura Chu, and Richard E. Gliklich
Background Lung cancer remains the leading cause of cancer death in the United States and worldwide is the most common cancer in both incidence and mortality, with an estimated 1.8 million deaths annually. 1 , 2 In 2021, lung cancer will
Demographic Disparities in Lung Cancer Mortality and Trends in the United States From 1999 Through 2020: A Population-Based CDC Database Analysis
Alexander J. Didier, Logan Roof, and James Stevenson
Background Lung cancer is the leading cause of cancer-related mortality in the United States and is projected to account for 127,070 deaths in 2023. 1 Lung cancer is comprised of 2 major histologic subtypes: non–small cell lung cancer (NSCLC
Low Provider Knowledge Is Associated With Less Evidence-Based Lung Cancer Screening
Jennifer A. Lewis, Heidi Chen, Kathryn E. Weaver, Lucy B. Spalluto, Kim L. Sandler, Leora Horn, Robert S. Dittus, Pierre P. Massion, Christianne L. Roumie, and Hilary A. Tindle
Background Lung cancer is the leading cause of cancer mortality among men and women in the United States. 1 Approximately 70% of lung cancer cases are diagnosed at advanced stages when there are limited options for cure, 2 reflected by the current
Stereotactic Body Radiation Therapy Versus Nonradiotherapeutic Ablative Procedures (Laser/Cryoablation and Electrocautery) for Early-Stage Non–Small Cell Lung Cancer
Michael J. Baine, Richard Sleightholm, Beth K. Neilsen, David Oupický, Lynette M. Smith, Vivek Verma, and Chi Lin
Background Patients diagnosed with early-stage non–small cell lung cancer (NSCLC) have multiple evidence-based treatment options. Although lobectomy remains the standard of care in medically operable patients, up to 85% to 90% are not surgical
Screening for Lung Cancer: An Expert Review
Presented by: Ella A. Kazerooni, Jacob Sands, and Douglas E. Wood
The NCCN Guidelines for Lung Cancer Screening have played a significant role in shaping clinical practice and policy, leading to increased coverage for lung cancer screening, increased incidence of early-stage disease, decreased incidence of late
